Is CytomX Therapeutics Inc (CTMX) undervalued? · rev $138.1M
CytomX Therapeutics Inc (CTMX) is a biotechnology company listed on US.
This page asks whether CytomX Therapeutics Inc (CTMX) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Latest reported CTMX revenue for 2024-12-31 was $138.1M. Net income was $31.9M. Revenue was up 36.4% from 2023-12-31 to 2024-12-31. CTMX currently screens at market cap $653.1M.
CTMX currently screens at market cap $653.1M. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new CTMX 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare CTMX to the stock page model before you treat a low multiple as a gift.
Not investment advice.